ECOG 6202 A Phase II Trial of Bortezomib Plus Doxorubicin in Hepatocellular Carcinoma.

Trial Profile

ECOG 6202 A Phase II Trial of Bortezomib Plus Doxorubicin in Hepatocellular Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2014

At a glance

  • Drugs Bortezomib (Primary) ; Doxorubicin (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jun 2009 New source identified and integrated New Jersey Cancer Trial Connect.
    • 30 Jun 2009 Additional lead trial investigator Kasimis BS identified as reported by New Jersey Cancer Trial Connect
    • 26 Sep 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top